secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2024-06-28T23:59:59+00:00
Accession:  0001070081-24-000010
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CHMP issues negative opinion on Translarna renewal; PTC plans re-examination
----------------------------------------------------------------------------

- CHMP issued negative opinion on renewal of conditional marketing authorization for Translarna (ataluren) for nmDMD.
- Negative opinion follows EC request for re-review; PTC will request re-examination per EMA guidelines.
- Marketing authorization remains in effect; Translarna expected on market through end of 2024 even if opinion upheld.
- CEO Klein: 'STRIDE real-world evidence should not be ignored'; expert panel agreed evidence shows significant efficacy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000010/0001070081-24-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000107008124000010/tmb-20240628x8k.htm
  HTML page:      https://secwatch.observer/filing/0001070081-24-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer